Verteporfin photodynamic therapy for neovascular age-related ...

More documents

Recommendations

Info

152 Appendix 1Appendix 6:Protocol for Pelli-Robson Contrast SensitivityAssessmentTest ConditionsThe Chart.• There are two charts to be used on each eye separately.• Each chart has different letter sequences but are otherwise identical.• The letters on the chart are organised into groups of three (i.e. triplets) therebeing two per line.• Within each triplet all letters have the same contrast.• The contrast decreases from one triplet to the next.• The division into triplets is indicated on the scoring sheet but not on the chartitself.• Unlike an acuity chart, in which the difficulty increases from line to line, in thePelli-Robson chart the difficulty increases in the middle of each line as well.Mounting the chart.• The chart should be hung so that the centre of the chart is at the level of thepatient’s eyes.• The patient should be seated on a chair that can have the height adjusted orthe chart can be moved up or down based on the height of the patient.Illuminating the chart.• The chart should be illuminated as uniformly as possible, so that theluminance of the white areas is between 60 to 120 foot candles.• Measure the illumination in all four corners of the chart to ensure that this isuniform.• The chart should be used in the same setting for all patients and at every visiti.e. located within a specified area or hung within a illuminated frame.• Avoid glare.Supplier of ETDRS chartsPelli-Robson LogMAR ETDRS Chart Panels can be obtained from:Clement Clarke InternationalEdinburgh Way,Harlow,EssexTel: 01279 414969Fax: 01279 635232
DOI: 10.3310/hta16060Health Technology Assessment 2012; Vol. 16: No. 6153Contrast Sensitivity Testing• Test patients before adding drugs to the conjunctival sac.• Test CS after logMAR visual acuity testing has been completed.• If the patient was refracted at 2 M add +0.5 D to correction, or if refracted at4M add +0.75 D.• The patient must sit one metre from the chart.• Test the right eye then the left eye.• The eye not being tested must be covered.• Test the right eye with the chart V, R and S as the first triplet.• Test the left eye with the chart that contains H, S and Z as the first triplet.• The charts should remain hidden from view until the eye is ready for testing.Recording the patient’s performance.• Complete the header of the record worksheet.• Ask the patient to name each letter on the chart starting with the dark letterson the upper left-hand corner and reading horizontally across the entire line.• The lighter letters can take some time to appear so ask the patient to keeplooking and not give up too soon• Do not agree or disagree with the patient. You may encourage the patient tocontinue to read.• Circle each letter read correctly and cross out each letter read incorrectly.• Leave letters not attempted unmarked.• Test the right eye then the left eye.Do not let the patient give up too soon. Patients should be made to guess even if theybelieve the letters are completely invisible. Always allow several seconds for the faintestletters to appear, but do not let the patient give up until he or she has guessed incorrectly 2of 3 letters in a triplet. The reliability of the results depend on the consistency of theexaminer’s approach.Scoring the test. The patient’s sensitivity is indicated by the faintest triplet for which 2 of the3 letters are named correctly. The log contrast sensitivity for this triplet is given by thenumber on the worksheet nearest to the triplet. Enter this number as the Log ContrastSensitivity Score.© Queen’s Printer and Controller of HMSO 2012. This work was produced by Reeves et al. under the terms of a commissioning contract issued by theSecretary of State for Health.
Page 5 and 6:
DOI: 10.3310/hta16060Health Technol
Page 12 and 13:
xExecutive summaryretreat on criter
Page 14 and 15:
xiiExecutive summaryof data, with i
Page 16 and 17:
2 Introductionon-going or new clini
Page 18 and 19:
4 Introductionof VPDT in routine cl
Page 21 and 22:
Page 23 and 24:
Page 25 and 26:
Page 27 and 28:
Page 29 and 30:
Page 31:
Page 34 and 35:
20 Key changes to the protocolThese
Page 36 and 37:
22 Key changes to the protocolCentr
Page 38 and 39:
24 Key changes to the protocolADVER
Page 40 and 41:
26 Key changes to the protocolPlan
Page 42 and 43:
28 Key changes to the protocolClass
Page 44 and 45:
30 Key changes to the protocolFor i
Page 46 and 47:
32 Key changes to the protocolIn ad
Page 48 and 49:
34 Key changes to the protocolsites
Page 52 and 53:
38 Results (1) - study cohortTABLE
Page 54 and 55:
Page 56 and 57:
Page 58 and 59:
Page 60 and 61:
46 Results (2) - objectives A, B, C
Page 62 and 63:
Page 64 and 65:
Page 66 and 67:
Page 69 and 70:
Page 71 and 72:
Page 73 and 74:
Page 75 and 76:
Page 77:
Page 80 and 81:
66 Discussion of resultsStrengths a
Page 82 and 83:
68 Discussion of resultsThe VPDT st
Page 84 and 85:
70 Discussion of resultsOur analyse
Page 86 and 87:
72 Discussion of resultsA further c
Page 88 and 89:
74 Discussion of resultsVPDT. It is
Page 91 and 92:
Page 93 and 94:
Page 95:
Page 98 and 99:
84 References16. Stelmack J. Qualit
Page 100 and 101:
86 References49. Guymer RH, Chiu AW
Page 102 and 103:
88 References83. Margrain TH. Minim
Page 104 and 105:
90 Appendix 1THE VERTEPORFIN PHOTOD
Page 106 and 107:
92 Appendix 11. Overview of Manual
Page 108 and 109:
94 Appendix 1And, if also collectin
Page 110 and 111:
96 Appendix 1more patients in the v
Page 112 and 113:
98 Appendix 12.4 Limitations of the
Page 114 and 115:
100 Appendix 1Box 2 Key advantages
Page 116 and 117: 102 Appendix 14. Study population4.
Page 118 and 119: 104 Appendix 15. Recruitment to the
Page 120 and 121: 106 Appendix 16. Background data co
Page 122 and 123: 108 Appendix 1Table 1: Schedule of
Page 124 and 125: 110 Appendix 1The Verteporfin Photo
Page 126 and 127: 112 Appendix 1• Additional clinic
Page 128 and 129: 114 Appendix 18. Recording adverse
Page 130 and 131: 116 Appendix 1level of benefit from
Page 132 and 133: 118 Appendix 1• comparison of num
Page 134 and 135: 120 Appendix 110.6 Sub-group analys
Page 136 and 137: 122 Appendix 112. Data issues12.1 D
Page 138 and 139: 124 Appendix 113. Organisation13.1
Page 140 and 141: 126 Appendix 114. References[1] Ref
Page 142 and 143: 128 Appendix 1Barnes RM, Gee L, Tay
Page 144 and 145: 130 Appendix 1Appendix 1: Classifyi
Page 146 and 147: 132 Appendix 1Liverpool re-treatmen
Page 148 and 149: 134 Appendix 1Service StructurePlea
Page 150 and 151: 136 Appendix 1Has your photographer
Page 152 and 153: 138 Appendix 1There are many differ
Page 154 and 155: 140 Appendix 1testing on vision tes
Page 156 and 157: 142 Appendix 1something to do with
Page 158 and 159: 144 Appendix 1College of Ophthalmol
Page 160 and 161: 146 Appendix 1Appendix 5:Protocol f
Page 162 and 163: 148 Appendix 16.2 Subjective Refrac
Page 164 and 165: 150 Appendix 1• The patient shoul
Page 168 and 169: 154 Appendix 18. It is customary to
Page 170 and 171: 156 Appendix 1Early or Transit Phas
Page 172 and 173: 158 Appendix 1
Page 174 and 175: 160 Appendix 1---------------------
Page 180 and 181: 166 Appendix 1Appendix 9:Site imple
Page 182 and 183: 168 Appendix 1Option 2 - units inte
Page 184 and 185: 170 Appendix 1Dos and Don’tsDosDo
Page 186 and 187: 172 Appendix 1Resource use question
Page 188 and 189: 174 Appendix 1Appendix 11: Recommen
Page 190 and 191: 176 Appendix 1ADVERSE REACTION AND
Page 192 and 193: 178 Appendix 1acute Trust; note tha
Page 194 and 195: 180 Appendix 1Ophthalmologistrespon
Page 197 and 198: DOI: 10.3310/hta16060Health Technol
Page 203: DOI: 10.3310/hta16060Health Technol
Page 206 and 207: 192 Appendix 3manufacturer’s pers
Page 216:
FeedbackThe HTA programme and the a
show all

Verteporfin photodynamic therapy for neovascular age-related ...

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?